Debate: Not all money is equal

Session Overview

Advanced therapies are stretching not just science and regulation but the very design of capital itself. Across Europe, a growing sentiment has emerged that traditional venture capital may be misaligned with the biological, manufacturing and regulatory realities of cell and gene therapies. Yet without VC, many of these breakthroughs would never leave the lab.

In a tightly moderated debate format, founders, investors, manufacturers and system leaders will debate whether capital is truly neutral, or whether time horizons, governance models and incentive structures actively shape clinical and commercial outcomes.

A serious, examination of what kind of capital advanced therapies actually need and whether Europe is funding innovation effectively, or simply funding it familiarly.

Audience vote before and after the debate will reveal whether minds have changed.